FDA: Wyeth's DTC for ReFacto has unsubstantiated safety claims

A Wyeth Pharmaceuticals direct-to-consumer brochure for ReFacto antihemophilic factor contains unsubstantiated safety claims, according to an FDA notice of violation letter. The brochure, titled “Bob's World,” contained a “Pathogen Safety” sub-section claiming state-of-the-art manufacturing techniques to optimize pathogen safety.
You must be a registered member of MMM to post a comment.

Next Article in Pharmaceutical